Pfizer Inc. has agreed to buy a privately held drugmaker developing medicines for a life-threatening respiratory virus, a deal with which the big drugmaker aims to bolster its push in combating infectious diseases.
Pfizer said Thursday that it had reached a deal to buy ReViral Ltd. and its experimental drug sisunatovir for up to $525 million if milestones are met.
To Read the Full Story
This post first appeared on wsj.com
